Novavax Earns $125 Million Milestone Payment From Sanofi's Phase 3 Vaccine Trial in Europe

MT newswire2026/10/29 14:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10:36 AM EDT, 10/29/2026 (MT Newswires) -- Novavax (NVAX) has earned a $125 million milestone payment related to Sanofi's (SNY) initiation of a phase 3 influenza-COVID-19 combination vaccine trial in Europe using Novavax's Nuvaxovid COVID-19 vaccine, according to a Thursday statement. The trial will evaluate the combination of Nuvaxovid with Sanofi's Efluelda/Fluzone High-Dose vaccine in adults aged at least 60 years old, Novavax said. The companies' collaboration and license agreement for Nuvaxovid also entitles Novavax to additional milestone payments and royalties on sales, according to the statement. Price: 10.46, Change: +0.14, Percent Change: +1.31

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03